BLAINJECTIONINJECTABLE
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AUKELSO (denosumab-kyqq) by Biocon is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AUKELSO (denosumab-kyqq) is a monoclonal antibody biosimilar that blocks RANK ligand to inhibit osteoclast formation and bone resorption. It is indicated for patients requiring RANK ligand inhibition across bone-related conditions. This is a reference product biosimilar entering a competitive immunology and bone health market.
Launch
Early-stage biosimilar launch with moderate competitive pressure (30/100); commercial teams will focus on payer negotiations, provider education, and market penetration in an established category.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AUKELSO offers entry or mid-level career exposure to biosimilar commercialization, payer strategy, and competitive market dynamics in a high-value therapeutic area. The launch phase provides opportunity to shape early positioning, but career growth will depend on the product's competitive trajectory and Biocon's long-term commercial commitment.
Brand Manager
Worked on AUKELSO at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.